<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029649</url>
  </required_header>
  <id_info>
    <org_study_id>19-01-0083</org_study_id>
    <nct_id>NCT04029649</nct_id>
  </id_info>
  <brief_title>Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Ulcerative Colitis</brief_title>
  <official_title>The Role of Beta-1,3/1,6-D-Glucan From Mycelium Extract of Indonesian Ganoderma Lucidum on Ulcerative Colitis: A Double-Blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fakultas Kedokteran Universitas Indonesia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the efficacy and safety of Beta-1,3/1,6-D-Glucan from
      mycelium extract of Ganoderma lucidum on ulcerative colitis
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Quality of Life: SF-36 questionnaire</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>Quality of Life is assessed by Indonesian validated Short Form 36 (SF-36) questionnaire. This questionnaire consist of 36 items/questions that evaluate quality of life in some elements. The elements are change in health (1 item), general health perception (5 items), energy/fatigue (4 items), mental health (5 items), social functioning (2 items), pain (2 items), physical functioning (10 items), role limitations due to emotional problems (3 items) and role limitations due to physical problems (4 items). The score from each question will be summed. Minimum score is 36 and maximum score is 138. Higher score indicates higher quality of life and lower score indicates lower quality of life. Higher score post intervention administration represents a positive outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of C-Reactive Protein (CRP) level</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>Level of CRP is obtained from laboratory test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>ESR is obtained from laboratory test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Tumor Necrosis Factor Alpha (TNF-α) level</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>Level of TNF-α is obtained from laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Interleukin 6 (IL-6) level</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>Level of IL-6 is obtained from laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of fecal calprotectin level</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>Level of fecal calprotectin is obtained from stool examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Mayo score</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>Mayo score is assessed from colonoscopy. 0 = normal 1 = mild (erythema, decreased vascular pattern, mild friability) 2 = moderate (marked erythema, absent vascular pattern, friability, erosions) 3 = severe (spontaneous bleeding, ulceration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with neutrophils infiltrating crypt epithelium in colon biopsy</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>Colon biopsy is obtained from colonoscopy and histopathology examination</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>30, 60 and 90 days</time_frame>
    <description>Number of participants with AE in this study</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with serious adverse events (SAEs)</measure>
    <time_frame>30, 60 and 90 days</time_frame>
    <description>Number of participants with SAEs in this study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Beta-1,3/1,6-D-Glucan Ganoderma lucidum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group received capsule contains 180 mg Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum with dose 3x1 capsule a day for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group received empty capsule with dose 3x1 capsule a day for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta-1,3/1,6-D-Glucan</intervention_name>
    <description>Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days</description>
    <arm_group_label>Beta-1,3/1,6-D-Glucan Ganoderma lucidum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule three times daily for 90 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥18 years old

          -  ulcerative colitis patients who are treated by 5-aminosalicylic acid (5-ASA) 3x500 mg

          -  agreed to participate in this study

        Exclusion Criteria:

          -  ulcerative colitis patients who are treated by corticosteroid, immunosuppressive
             agents and biologic agents

          -  allergic to Ganoderma lucidum

          -  could not be randomised and participate in this study by clinical judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcellus Simadibrata</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division Of Gastroenterology Department Of Internal Medicine Faculty Of Medicine Universitas Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcellus Simadibrata</last_name>
    <phone>0816920448</phone>
    <email>marcellussimadibrata57@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>RSUPN dr. Cipto Mangunkusumo (Cipto Mangunkusumo Hospital)</name>
      <address>
        <city>Jakarta</city>
        <state>Jakarta Pusat</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Marcellus Simadibrata</last_name>
      <phone>0816920448</phone>
      <email>marcellussimadibrata57@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fakultas Kedokteran Universitas Indonesia</investigator_affiliation>
    <investigator_full_name>Marcellus Simadibrata, Prof. PhD., SpPD, KGEH</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Beta-1,3/1,6-D-Glucan</keyword>
  <keyword>Ganoderma lucidum</keyword>
  <keyword>Ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT04029649/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

